WO2019124854A1 - Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci - Google Patents
Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci Download PDFInfo
- Publication number
- WO2019124854A1 WO2019124854A1 PCT/KR2018/015687 KR2018015687W WO2019124854A1 WO 2019124854 A1 WO2019124854 A1 WO 2019124854A1 KR 2018015687 W KR2018015687 W KR 2018015687W WO 2019124854 A1 WO2019124854 A1 WO 2019124854A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fraction
- dry eye
- eye syndrome
- licorice
- extract
- Prior art date
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 77
- 206010013774 Dry eye Diseases 0.000 title claims abstract description 74
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 230000028327 secretion Effects 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 42
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 39
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 39
- 229940010454 licorice Drugs 0.000 claims description 39
- 241000736199 Paeonia Species 0.000 claims description 37
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 37
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 15
- 235000013376 functional food Nutrition 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 15
- 230000004660 morphological change Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 208000003464 asthenopia Diseases 0.000 claims description 6
- 239000000490 cosmetic additive Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 2
- 239000012223 aqueous fraction Substances 0.000 claims description 2
- 210000005252 bulbus oculi Anatomy 0.000 claims description 2
- 239000002034 butanolic fraction Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 2
- 239000002044 hexane fraction Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 6
- 238000003809 water extraction Methods 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000002137 ultrasound extraction Methods 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 abstract description 12
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 6
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 6
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 4
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract 2
- 210000001508 eye Anatomy 0.000 description 15
- 229940069445 licorice extract Drugs 0.000 description 15
- 230000008859 change Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940051810 licorice root extract Drugs 0.000 description 5
- 235000020725 licorice root extract Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000017060 Arachis glabrata Nutrition 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 4
- 235000010777 Arachis hypogaea Nutrition 0.000 description 4
- 235000018262 Arachis monticola Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004561 lacrimal apparatus Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- 235000020232 peanut Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000221017 Euphorbiaceae Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 241000192043 Echinochloa Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a pharmaceutical composition for preventing or treating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient, and a health functional food for preventing or ameliorating dry eye syndrome comprising the mixed extract or the fraction thereof as an active ingredient .
- Dry eye syndrome is not simply a tear defect, but it causes eye discomfort, eye fatigue, decreased visual acuity, and instability of the tear layer due to inflammation of the tear and ocular surface (cornea and conjunctiva) .
- inflammation plays an important role in infiltration of inflammatory cells, increased expression of immune activation molecules and adhesion molecules, Th1 and Th17 responses, abnormalities of apoptotic markers and chemokines have.
- dry eye syndrome is a common disease that occurs in about 20% of adults in Korea. Especially, global warming due to global climate change, especially El Ni ⁇ o phenomenon, and environmental pollution such as fine dust, There is no therapeutic or functional food.
- Paeonia lactiflora is a perennial plant belonging to the family Paeoniaceae and is native to parts of China, Siberia and Korea, and the herbal medicine and herbal medicines are defined as the roots of Paeonia lactiflora Pallas or other herbaceous plants .
- the pharmacological activities of peonies have been reported to inhibit platelet aggregation, to act on the circulatory system, to antitumor action, and to enhance immunity (Son Dong-Ju, Journal of the Korean Society of Food Science and Nutrition, 2002, 31, 511, 4, 445).
- Licorice ( Glycyrrhiza uralensis ) is a perennial herbaceous plant belonging to the soybean family.
- the pharmacological activity of licorice was evaluated by the antitumor effect of chronic hepatitis improvement, antidiabetic effect (Mae, Tatsumasa, et al., The Journal of nutrition 133.11 (2003): 3369-3377) , Korean Journal of Plant Resources 27.5 (2014): 401-414.), Ulcerative Colitis Inhibitory Effect (Lee, Keyong-Ho, and Ki-Hyeong Rhee., The Korean Journal of Food and Nutrition 23.4 -439.), Antioxidant effects (Woo, Koan-Sik, et al., Journal of the Korean Society of Food Science and Nutrition 36.6 (2007): 689-695).
- the present inventors have completed the present invention by confirming that a mixed extract of peony root and licorice, or a fraction thereof, can treat dry eye syndrome through an increase in tear secretion amount and inhibition of corneal morphological change.
- Another object of the present invention is to provide a composition for preventing or treating dry eye syndrome comprising a mixture of peony root and licorice root extract or a fraction thereof as an active ingredient.
- Another object of the present invention is to provide a health functional food for preventing or ameliorating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
- It is another object of the present invention to provide a feed composition for preventing or improving dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
- Another object of the present invention is to provide a quasi-drug composition for the prevention or treatment of dry eye syndrome comprising a mixture of peony root and licorice root extract or a fraction thereof as an active ingredient.
- Another object of the present invention is to provide an eye cosmetic additive composition for preventing or improving dry eye syndrome, which comprises a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
- Another object of the present invention is to provide a method for preventing or treating dry eye syndrome comprising administering to a subject a mixed extract of licorice and licorice or a fraction thereof.
- the peanut and licorice mixed extract of the present invention and the fractions thereof can be used for the development of a pharmaceutical composition for the prevention or treatment of dry eye syndrome since the amount of tear secretion due to dry eye syndrome and the change of corneal morphology can be significantly inhibited It will be possible.
- FIG. 1 is a photograph showing a change in the amount of tear secretion according to the administration of the mixed extract through an eye volume test sheet.
- FIG. 2 is a graph showing a quantitative change in the amount of tear secretion according to the mixed extract administration (*: p ⁇ 0.05 vs. Normal; #: p ⁇ 0.05 vs. dry eye).
- FIG. 3 is a photograph showing changes in the corneal morphology of rats upon administration of mixed extracts.
- FIG. 4 is a graph showing scores of corneal smoothness score in rats according to the mixed extract administration.
- the corneal smoothness score was evaluated by dividing the corneal morphology by 0 to 5 (zero point: no distortion, 1 point: distortion at 1/4 point, 2 points: 2/4 point , 3 points: Distortion at 3/4 point, 4 points: Distortion at all points, 5 points: Uncertainty of rounded shape due to severe distortion, #: p ⁇ 0.05 vs. dry eye).
- FIG. 5 is a graph showing a quantitative change in the amount of tear secretion according to administration of licorice extract (*: p ⁇ 0.05 vs. Normal).
- FIG. 6 is a photograph showing changes in the corneal morphology of rats upon administration of licorice extract.
- FIG. 7 is a graph showing the corneal smoothness score of rats according to administration of mixed extract (*: p ⁇ 0.05 vs. Normal).
- the inventors of the present invention have found that when a variety of studies are conducted to develop a therapeutic agent capable of effectively treating dry eye syndrome, a mixed extract of peony root and licorice or a fraction thereof shows an effect of treating dry eye syndrome.
- the above-mentioned mixed extracts or fractions of peanut and licorice not only significantly inhibited the decrease of tear secretion and changes in corneal morphology according to dry eye syndrome but also showed similar effects to the commercial drugs used for the treatment of dry eye syndrome there was.
- the technique for treating dry eye syndrome using the mixed extract or fraction has not been known at all and has been developed for the first time by the present inventors.
- the present invention provides a pharmaceutical composition for preventing or treating dry eye syndrome, which comprises a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
- the present invention also provides a composition for preventing, ameliorating or treating dry eye syndrome, comprising a mixture of peony root and licorice, or a fraction thereof as an active ingredient.
- the mixed extract of peanut and licorice having the preventive and therapeutic activity of dry eye syndrome can be extracted from various organs of natural, hybrid, and variant plants and can be extracted from various organs such as roots, stems, leaves, flowers, As well as extracts from plant tissue cultures.
- Paeonia lactiflora is a perennial herb that belongs to the family Paeoniaceae and is native to parts of China, Siberia and Korea.
- peonies are defined as the roots of Paeonia lactiflora or other plants, and peeled, dried and dried together with peel and peel are called peptone.
- the pharmacological activities of peonies have been reported to inhibit platelet aggregation, to act on the circulatory system, to antitumor action, and to enhance immunity.
- Glycyrrhiza uralensis is a perennial herbaceous plant belonging to the soybean family and may be used as a medicinal or sweetener by drying the roots.
- the pharmacological activity of licorice has been reported to improve chronic hepatitis by detoxification, anti - diabetic effect, anti - ulcer effect, ulcerative colitis inhibitory effect, antioxidant effect.
- the mixed extract may be extracted from roots, stems, leaves, flowers, or fruits of peony root and licorice, and is not particularly limited thereto.
- the mixed extract of peony root and licorice includes, but is not limited to, extracts from a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixed solvents thereof.
- the above extract may contain any one of the extract obtained by the extraction treatment, the diluted solution or the concentrate of the extract, the dried product obtained by drying the extract, or the adjusted product or the purified product.
- the alcohol may be butyl alcohol, ethyl alcohol, methyl alcohol or a water-soluble alcohol thereof.
- the water-soluble alcohol may be an alcohol in an amount of 0.1 to 100% by weight.
- fraction means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
- the fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art.
- a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting a mixed extract of peony root and licorice root is not particularly limited and may be carried out according to a method commonly used in the art.
- the fraction may be a hexane fraction, an ethyl acetate fraction, a butanol fraction or a water fraction of a mixture of peony root and licorice.
- the fractions may each comprise 0.01 to 100% by weight, more specifically 1 to 80% by weight, based on the total weight of the pharmaceutical composition.
- the kind of the fraction solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used.
- Non-limiting examples of the fraction solvent include polar solvents such as water and alcohol; And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more.
- polar solvents such as water and alcohol
- non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more.
- C1 to C4 alcohols can be specifically used.
- dry eye syndrome refers to dry eye syndrome, which is caused by inflammation of the lacrimal gland and decongestion of the cornea, inhibiting tear secretion, And abnormal conjunctival epithelial disorder caused by excessive dryness of the tears due to the dry eye syndrome and resulting in wounds of the cornea.
- prevention refers to any act that inhibits or delays the symptoms of dry eye syndrome by administration of a composition comprising the peony root extract of licorice and licorice, or fractions thereof, according to the present invention.
- treatment refers to any action that improves or alleviates the symptoms of dry eye syndrome by administration of a composition comprising the peony root extract and licorice root extract or fractions thereof according to the present invention.
- the composition may increase the secretion amount of tears or inhibit the morphological change of the cornea.
- the morphological change of the cornea may be due to excessive irritation of the tears, which may cause the surface of the cornea to become rugged and the rounded circle to warp and distort.
- the composition of the present invention may improve smoothness and flatness.
- the tear secretion amount was significantly increased in all the concentration groups when the mixed extract of peony root and Licorice was administered, and it was confirmed that the effect was increased depending on the concentration (FIGS. 1 and 2 ).
- the term "pharmaceutical composition” means a preparation intended for the prevention or treatment of disease, and may be formulated into various forms according to each ordinary method.
- it can be formulated into a form such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and the like, and can be formulated in the form of external preparations, suppositories and sterilized injection solutions.
- it can be formulated into an external preparation for eye, a form suitable for topical administration, for example, an eye drop, a cream, an ointment, a gel or a lotion.
- composition of the present invention may be prepared in the form of a pharmaceutical composition for preventing or treating dry eye syndrome, which further comprises an appropriate carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, (non-naturally occuring carrier).
- the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
- Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
- the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
- the dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction to the disease, the age, body weight, sex, history, or kind of the substance used as the active ingredient.
- the pharmaceutical composition of the present invention may be administered at a dose of from about 0.1 ng to about 1,000 mg / kg, in particular from 1 ng to 1,000 mg / kg, per adult, and the frequency of administration of the composition of the present invention is specifically limited However, it may be administered once a day or divided into several doses. The dose is not intended to limit the scope of the invention in any way.
- the present invention provides a method for treating dry eye syndrome comprising administering the pharmaceutical composition to a subject suffering from dry eye syndrome in a pharmaceutically effective amount.
- the term "individual” as used herein may include, without limitation, mammals including rats, livestock, and the like with dry eye syndrome.
- the "individual” may include companion animals.
- the companion animal refers to an animal living together with a human, and specific examples include, but are not limited to, mammals such as dogs, cats, hamsters, and guinea pigs, and birds such as parrots and canaries.
- composition may be administered in single or multiple doses in a pharmaceutically effective amount.
- the administration route of the pharmaceutical composition for preventing or treating dry eye syndrome of the present invention can be administered through any ordinary route as long as it can reach the target tissue.
- composition of the present invention may be administered orally, intraperitoneally, intramuscularly, subcutaneously, intradermally, transdermal patch, oral, intranasal, intrapulmonary, Intramuscular administration, intrathecal administration, intrarectal administration, and the like, and specifically administered orally.
- the present invention provides a health functional food for preventing or ameliorating dry eye syndrome comprising a mixed extract of peony root and licorice or a fraction thereof as an active ingredient.
- peanut, licorice, fraction, and dry eye syndrome in the health functional food of the present invention is as defined above.
- the term “improvement” means any action that alters or modifies dryness of the eye by orally administering the composition.
- the term "functional" as used in the present invention means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action.
- the health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art.
- the formulation of the health functional food may also be produced without limitation as long as the formulation is recognized as a health functional food.
- the health functional food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has advantages of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to improve the effect of preventing or improving dry eye syndrome.
- the health functional food is a food prepared by adding the mixed extract or fraction of the present invention to a food material such as beverage, tea, spice, gum, confectionery, or the like, or encapsulating, powdering, or suspending, But it has the advantage that there is no side effect that can occur when a drug is taken for a long time using a food as a raw material, unlike a general medicine.
- an eye cosmetic additive composition for preventing or improving dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
- the definition of the extract of Eisenhower extract, fraction, dry eye syndrome, prevention and improvement in the eye cosmetic additive composition is as defined above.
- the additive may be included in eye make-up products and may be effective in preventing or improving the disease.
- the composition may include eye make-up products.
- eye make-up cosmetic products include any one selected from the group consisting of eye pencil, eye liner, eye shadow, mascara, and eye makeup remover. have.
- a quasi-drug composition for preventing or improving dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
- Quasi-drug product in the present invention means products which are less active than drugs, for example, for the purpose of diagnosing, treating, improving, alleviating, treating or preventing a disease in a human or an animal.
- Quasi-drugs are products that are not used for medicines, such as fibers and rubber products used for the treatment and prevention of diseases of humans and animals, and are not acting directly or indirectly on the human body, These include sterilization and insecticides to prevent infectious diseases.
- the type and formulations of the quasi-drug composition of the present invention are not particularly limited, but may be disinfectant cleaner, shower foam, gagrin, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
- a feed composition for preventing or ameliorating dry eye syndrome comprising extracts of Euphorbiaceae or fractions thereof as an active ingredient.
- feed means any natural or artificial diet, single meal or the like or ingredients of the above formula for ingesting, ingesting, digesting or suitable for the individual.
- the kind of the feed is not particularly limited, and feeds conventionally used in the art can be used.
- feeds include vegetable feeds such as cereals, muscle roots, food processing busines logistics, algae, fibers, pharmaceuticals, buses, oils, pastes, pulses or cereals; Animal feeds such as proteins, inorganic substances, fats, oils, fats, oils, monocellular proteins, animal plankton or foods. These may be used alone or in combination of two or more.
- the tear secretion amount was significantly increased in all the concentration groups when the mixed extract of peony root and Licorice was administered, and it was confirmed that the effect was increased depending on the concentration (FIGS. 1 and 2 ).
- the above-mentioned results indicate that the mixed extract of peony root and licorice or its fractions can be used as a pharmaceutical composition for preventing dry eye disease or eye fatigue, for improving or ameliorating eye fatigue, a health functional food, an eye cosmetic additive, And it can be used effectively.
- the extracts were filtered, and the filtrate was concentrated under reduced pressure at about 50 ° C and dried to prepare a mixed extract.
- the experimental group consisted of the following: non-invasive normal group (NOR) with no abnormality, the disease caused by dry eye lacrimal gland by the method of Example 2.1 (JGT-50) administered with 50 mg / kg of the mixed extract of the present invention (JGT), a drug administration group (JGT-50) administered with 100 mg / kg of the mixed extract of the present invention (JGT- 100), the drug-administered group (JGT-250) in which 250 mg / kg of the mixed extract of the present invention (JGT) was administered.
- the drug containing the mixed extract of the present invention was prepared by dissolving the above dose in sterilized physiological saline containing 0.5% DMSO.
- the dry eye was additionally administered on the 5th day for 3 days.
- the animals were anesthetized and the change in color of the test strip was measured by tearing after 30 seconds of contact with the phenol-red thread volume test (FCI Opthalmics Zone Quick, Japan) And the efficacy of the drug was evaluated.
- composition of the test group and administration of the drug were carried out in the same manner as in Example 2.2.
- the animals were anesthetized and photographed using a stereoscopic microsope (Olympus, Japan) equipped with a fiberoptic ring illuminator. Changes in corneal morphology were assessed by grading the degree of distortion of the rounded circle shape of the circular light reflected on the corneal epithelium from 0 to 5. 0 point: No distortion, 1 point: Distortion at 1/4 point, 2 points: Distortion at 2/4 point, 3 points: Distortion at 3/4 point, 4 points: Distortion at all points, 5 point: Distortion at severe point Can not recognize the shape of the round circle.
- the morphological changes of the cornea were evaluated.
- the tears secreted from the external lacrimal gland formed a tear film, and the smooth and flat surface state was maintained.
- the smooth and flat surface state was maintained.
- abnormalities in the tear film covering the cornea resulted in degeneration of the epithelium of the corneal epithelium and smooth surface of the cornea, so that the rounded shape was distorted and distorted.
- JGT-100 and JGT-250 significantly inhibited corneal morphological changes such as the disease group (FIGS. 3 and 4).
- the tear secretion amount was measured using the method of Example 2.2 in order to confirm the therapeutic effect of the licorice extract extracted by the method of Example 1 with dry liquorice alone.
- the dose of licorice extract was 84 mg / kg, the dose of Licorice based on JGT-250 (250 mg / kg dose).
- the tear secretion amount of the licorice extract-treated group was not significantly different from that of the dry eye syndrome group, confirming that the licorice extract did not increase the tear secretion amount.
- Example 2.3 In order to confirm the therapeutic effect of dry eye extract of licorice root extract, the change of corneal morphology was confirmed by the method of Example 2.3.
- the dose of licorice extract was 84 mg / kg, the dose of Licorice based on JGT-250 (250 mg / kg dose).
- the licorice extract alone did not affect the amount of tear secretion, and had no effect of inhibiting the corneal morphological change. Thus, it was confirmed that it was not suitable as a composition for treating dry eye syndrome.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne une composition pharmaceutique pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant, en tant que principe actif, un extrait mixte de Paeonia lactiflora et Glycyrrhiza uralensis ou une fraction de celui-ci, et un aliment santé fonctionnel pour prévenir ou soulager le syndrome de sécheresse oculaire, contenant, en tant que principe actif, l'extrait mixte ou une fraction de celui-ci. L'extrait mixte de Paeonia lactiflora et Glycyrrhiza uralensis ou une fraction de celui-ci de la présente invention peut inhiber de manière significative une réduction de la sécrétion de larmes et des changements topographiques de la cornée, provoqués par le syndrome de sécheresse oculaire, et peut donc être fourni en tant que principe actif d'une composition pharmaceutique et d'un aliment santé fonctionnel pour prévenir ou traiter le syndrome de sécheresse oculaire et dans une méthode de traitement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170178782A KR102070850B1 (ko) | 2017-12-22 | 2017-12-22 | 혼합 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 또는 치료용 조성물 |
KR10-2017-0178782 | 2017-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019124854A1 true WO2019124854A1 (fr) | 2019-06-27 |
Family
ID=66993602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/015687 WO2019124854A1 (fr) | 2017-12-22 | 2018-12-11 | Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102070850B1 (fr) |
WO (1) | WO2019124854A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102466377B1 (ko) * | 2020-06-19 | 2022-11-14 | 대한민국(농촌진흥청장) | 꽃양귀비 추출물 또는 이의 분획물을 유효성분으로 함유하는 안구건조증 또는 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물 |
KR20220131018A (ko) | 2021-03-19 | 2022-09-27 | 주식회사 티스템 | 무막줄기세포추출물을 포함하는 안구건조증 치료용 조성물 및 이에 의해 제조된 점안액 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040058015A1 (en) * | 2000-06-01 | 2004-03-25 | Yuanjin Tao | Compositions and methods for treating eye discomfort and eye disease |
CN102210821A (zh) * | 2011-05-15 | 2011-10-12 | 王春兰 | 一种治疗干眼症的中药 |
CN104383296A (zh) * | 2014-12-04 | 2015-03-04 | 湖南中医药大学 | 一种用于治疗干眼症的中药组合物及其制备方法 |
CN104435685A (zh) * | 2014-11-30 | 2015-03-25 | 顾蔷怡 | 一种治疗干眼症的药物及其制备方法 |
KR20170004245A (ko) * | 2015-07-01 | 2017-01-11 | 김무연 | 안과 질환의 예방 또는 치료용 약학 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160025187A (ko) * | 2014-08-27 | 2016-03-08 | 우용규 | 황백 추출물을 이용한 피부냉감용 생약조성물 및 이의 제조방법과 이를 이용한 피부개선제품 |
-
2017
- 2017-12-22 KR KR1020170178782A patent/KR102070850B1/ko active IP Right Grant
-
2018
- 2018-12-11 WO PCT/KR2018/015687 patent/WO2019124854A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040058015A1 (en) * | 2000-06-01 | 2004-03-25 | Yuanjin Tao | Compositions and methods for treating eye discomfort and eye disease |
CN102210821A (zh) * | 2011-05-15 | 2011-10-12 | 王春兰 | 一种治疗干眼症的中药 |
CN104435685A (zh) * | 2014-11-30 | 2015-03-25 | 顾蔷怡 | 一种治疗干眼症的药物及其制备方法 |
CN104383296A (zh) * | 2014-12-04 | 2015-03-04 | 湖南中医药大学 | 一种用于治疗干眼症的中药组合物及其制备方法 |
KR20170004245A (ko) * | 2015-07-01 | 2017-01-11 | 김무연 | 안과 질환의 예방 또는 치료용 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20190076732A (ko) | 2019-07-02 |
KR102070850B1 (ko) | 2020-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010104309A2 (fr) | Compositions pour prévenir ou améliorer des maladies gastro-intestinales | |
WO2010058926A2 (fr) | Composition pharmaceutique contenant un extrait de gingembre ou du shogaol | |
WO2011059292A2 (fr) | Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs | |
WO2021049864A1 (fr) | Composition permettant d'améliorer le syndrome de l'œil sec contenant un extrait d'aralia elata | |
WO2019124854A1 (fr) | Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci | |
KR101764786B1 (ko) | 호장근 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 및 치료용 조성물 | |
WO2019146881A1 (fr) | Composition pour la prévention ou le traitement du syndrome de l'œil sec, contenant un extrait d'aucuba japonica | |
WO2018164325A1 (fr) | Composition permettant de soigner les symptômes du syndrome climatère féminin | |
WO2018111042A2 (fr) | Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif | |
WO2018190501A1 (fr) | Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng | |
WO2018230942A1 (fr) | Composition contenant un extrait ou une fraction d'extrait de reynoutria japonica pour prévenir et traiter le syndrome de l'œil sec | |
WO2017176001A1 (fr) | Composition destinée à soulager les symptômes de la ménopause chez les femmes, contenant de l'extrait de sasa quelpaertensis nakai | |
WO2011139118A2 (fr) | Composition pharmaceutique et composition d'aliment naturel fonctionnel pour la prévention, le traitement ou l'amélioration de maladies de type dyskinésie gastro-intestinale | |
WO2020138834A1 (fr) | Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée | |
WO2016129902A1 (fr) | Composition pour prévenir, soulager ou traiter le syndrome d'épuisement professionnel | |
WO2020116996A1 (fr) | Composition pharmaceutique contenant un extrait d'aucuba japonica pour prévenir ou traiter la dégénérescence maculaire | |
WO2020080673A1 (fr) | Composition permettant de prévenir ou de traiter une maladie rétinienne contenant un extrait de centella asiatica | |
WO2018106009A1 (fr) | Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires | |
WO2019098615A1 (fr) | Composition contenant un extrait ou une fraction d'extrait d'aster k oraiensis pour la prévention ou le traitement de l'œil sec | |
WO2018080157A1 (fr) | Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif | |
WO2017069506A1 (fr) | Composition pharmaceutique pour la prévention et le traitement de symptômes de ménopause, contenant, comme principe actif, un mélange d'extraits de réglisse et de curcuma longa | |
WO2013024960A1 (fr) | Composition médicale contenant un extrait de stauntonia hexaphylla | |
WO2018190638A1 (fr) | Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max | |
KR100807645B1 (ko) | 위장질환 치료 및 예방용 조성물 및 그의 제조방법 | |
WO2020071620A1 (fr) | Composition pharmaceutique destinée à la prévention ou au traitement de maladies neurodégénératives, contenant un extrait d'angelica gigas nakai ou un mélange d'extraits d'angelica gigas nakai et de brocoli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18892418 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18892418 Country of ref document: EP Kind code of ref document: A1 |